10.6.2014
EN
Official Journal of the European Union
C 175/14
Judgment of the Court (Sixth Chamber) of 10 April 2014 — Acino AG v European Commission
(Case C-269/13 P) (1)
((Appeal - Medicinal products for human use - Suspension of the marketing and the withdrawal of certain consignments of medicinal products containing the active ingredient Clopidogrel - Variation of marketing authorisations - Prohibition on marketing - Regulation (EC) No 726/2004 and Directive 2001/83/EC - Precautionary principle - Proportionality - Obligation to state reasons))
2014/C 175/16
Language of the case: German
Parties
Appellant: Acino AG (represented by: R. Buchner and E. Burk, Rechtsanwälte)
Other party to the proceedings: European Commission (represented by: M. Šimerdová and B.-R. Killmann, acting as Agents)
Re:
Appeal against the judgment of the General Court (Seventh Chamber) of 7 March 2013 in Case T-539/10 Acino v Commission, in so far as that Court dismissed an application for annulment of Commission Decisions C (2010) 2203, C (2010) 2205, C (2010) 2210 and C (2010) 2218 of 29 March 2010 and Commission Decisions C (2010) 6430, C (2010) 6432, C (2010) 6434 and C (2010) 6435 of 16 September 2010, relating to the suspension of the marketing of medicinal products for human use containing the active ingredient Clopidogrel manufactured at a certain site, the withdrawal of consignments of those medicinal products from the market, the variation of the marketing authorisations and the prohibition on marketing those medicinal products — Precautionary principle — Proportionality — Obligation to state reasons
Operative part of the judgment
The Court:
1.
Dismisses the appeal.
2.
Orders Acino AG to pay the costs.
(1) OJ C 215, 27.07.2013.
Full & Egal Universal Law Academy